WallStSmart

Boston Scientific Corp (BSX)vsCVRx Inc (CVRX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Boston Scientific Corp generates 34214% more annual revenue ($21.00B vs $61.19M). BSX leads profitability with a 17.5% profit margin vs -84.9%. BSX earns a higher WallStSmart Score of 72/100 (B).

BSX

Strong Buy

72

out of 100

Grade: B

Growth: 7.3Profit: 7.0Value: 6.7Quality: 5.5
Piotroski: 5/9Altman Z: 1.78

CVRX

Avoid

31

out of 100

Grade: F

Growth: 7.3Profit: 2.0Value: 6.7Quality: 4.5
Piotroski: 3/9Altman Z: -7.47
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BSXOvervalued (-10.0%)

Margin of Safety

-10.0%

Fair Value

$39.07

Current Price

$42.98

$3.91 premium

UndervaluedFair: $39.07Overvalued
CVRXUndervalued (+70.8%)

Margin of Safety

+70.8%

Fair Value

$20.80

Current Price

$2.88

$17.92 discount

UndervaluedFair: $20.80Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BSX6 strengths · Avg: 8.2/10
Market CapQuality
$62.29B9/10

Large-cap with strong market position

PEG RatioValuation
0.608/10

Growing faster than its price suggests

P/E RatioValuation
17.5x8/10

Attractively priced relative to earnings

Price/BookValuation
2.5x8/10

Reasonable price relative to book value

Operating MarginProfitability
22.9%8/10

Strong operational efficiency at 22.9%

Free Cash FlowQuality
$1.28B8/10

Generating 1.3B in free cash flow

CVRX1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
15.6%8/10

15.6% revenue growth

Areas to Watch

BSX1 concerns · Avg: 4.0/10
Altman Z-ScoreHealth
1.784/10

Distress zone — elevated risk

CVRX4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$76.73M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-180.9%2/10

ROE of -180.9% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : BSX

The strongest argument for BSX centers on Market Cap, PEG Ratio, P/E Ratio. Profitability is solid with margins at 17.5% and operating margin at 22.9%. PEG of 0.60 suggests the stock is reasonably priced for its growth.

Bull Case : CVRX

The strongest argument for CVRX centers on Revenue Growth. Revenue growth of 15.6% demonstrates continued momentum.

Bear Case : BSX

The primary concerns for BSX are Altman Z-Score.

Bear Case : CVRX

The primary concerns for CVRX are EPS Growth, Market Cap, Piotroski F-Score. Debt-to-equity of 2.98 is elevated, increasing financial risk.

Key Dynamics to Monitor

BSX profiles as a mature stock while CVRX is a growth play — different risk/reward profiles.

CVRX carries more volatility with a beta of 0.76 — expect wider price swings.

CVRX is growing revenue faster at 15.6% — sustainability is the question.

BSX generates stronger free cash flow (1.3B), providing more financial flexibility.

Bottom Line

BSX scores higher overall (72/100 vs 31/100), backed by strong 17.5% margins. CVRX offers better value entry with a 70.8% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

CVRx Inc

HEALTHCARE · MEDICAL DEVICES · USA

CVRx, Inc. develops implantable technology for the treatment of patients with high blood pressure / hypertension and heart failure.

Want to dig deeper into these stocks?